Gouty Arthritis — Long Term Study of Canakinumab (ACZ885) in Patients With Gout
Citation(s)
A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Were Given Canakinumab at the Time of Gout Flare